11 research outputs found
Efficacy of orally administered fluralaner (BravectoTM) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs
BACKGROUND : This laboratory study compared the efficacy of Bravecto™ (fluralaner), formulated as a chewable
tablet, with the efficacy of Advocate® (imidacloprid/moxidectin), formulated for topical administration, against
naturally acquired generalized demodicosis in dogs.
METHODS : Sixteen dogs, all diagnosed with generalized demodectic mange, were randomly allocated to two equal
groups. Bravecto™ chewable tablets were administered once orally at a minimum dose of 25 mg fluralaner/kg body
weight to one group of dogs, while the second group was treated topically on three occasions at 28-day intervals
with Advocate® at a minimum dose of 10 mg imidacloprid/kg body weight and 2.5 mg moxidectin/kg body weight.
Mites were counted in skin scrapings and demodectic lesions were evaluated on each dog before treatment and at
28-day intervals thereafter over a 12 week study period. Deep skin scrapings (~4 cm2) were made from the same five
sites on each dog at each subsequent examination.
RESULTS : After single oral administration of Bravecto™ chewable tablets, mite numbers in skin scrapings were reduced
by 99.8% on Day 28 and by 100% on Days 56 and 84. Mite numbers in the dogs treated topically on three occasions at
28-day intervals with Advocate® were reduced by 98.0% on Day 28, by 96.5% on Day 56 and by 94.7% on Day 84.
Statistically significantly (P ≤ 0.05) fewer mites were found on Days 56 and 84 on the Bravecto™ treated dogs
compared to Advocate® treated dogs. A marked decrease was observed in the occurrence of erythematous patches,
crusts, casts and scales in the dogs treated with Bravecto™ and in the occurrence of erythematous patches in the dogs
treated with Advocate®. With the exception of one dog in each treated group, all dogs exhibited hair regrowth ≥ 90%
at the end of the study in comparison with their hair-coat at study start.
CONCLUSIONS : Single oral administration of Bravecto™ chewable tablets is highly effective against generalized
demodicosis, with no mites detectable at 56 and 84 days following treatment. In comparison, Advocate®, administered
three times at 28-day intervals, is also highly effective against generalized demodicosis, but most dogs still harboured
mites at all assessment time points. Both treatments resulted in a marked reduction of skin lesions and increase of hair re-growth 12 weeks after the initial treatment.http://www.parasitesandvectors.comam201
Computational Lipidology: Predicting Lipoprotein Density Profiles in Human Blood Plasma
Monitoring cholesterol levels is strongly recommended to identify patients at risk for myocardial infarction. However, clinical markers beyond “bad” and “good” cholesterol are needed to precisely predict individual lipid disorders. Our work contributes to this aim by bringing together experiment and theory. We developed a novel computer-based model of the human plasma lipoprotein metabolism in order to simulate the blood lipid levels in high resolution. Instead of focusing on a few conventionally used predefined lipoprotein density classes (LDL, HDL), we consider the entire protein and lipid composition spectrum of individual lipoprotein complexes. Subsequently, their distribution over density (which equals the lipoprotein profile) is calculated. As our main results, we (i) successfully reproduced clinically measured lipoprotein profiles of healthy subjects; (ii) assigned lipoproteins to narrow density classes, named high-resolution density sub-fractions (hrDS), revealing heterogeneous lipoprotein distributions within the major lipoprotein classes; and (iii) present model-based predictions of changes in the lipoprotein distribution elicited by disorders in underlying molecular processes. In its present state, the model offers a platform for many future applications aimed at understanding the reasons for inter-individual variability, identifying new sub-fractions of potential clinical relevance and a patient-oriented diagnosis of the potential molecular causes for individual dyslipidemia
VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly
Altered apolipoprotein AI metabolism in subjects with type IIA heterozygous familial hypercholesterolemia: a kinetic study
International audienc